The BET-inhibitor PFI-1 diminishes AR/AR-V7 signaling in prostate cancer cells
The bromodomain and extra-terminal (BET) family of proteins provides a scaffolding platform for the recruitment and tethering of transcription factors to acetylated chromatin, thereby modulating gene expression. In this study, we evaluated the efficacy of the BET-inhibitor PFI-1 to diminish AR/AR-V7 signaling and proliferation in castration-resistant prostate cancer cells.
Prostate-specific antigen and androgen receptor (AR) protein were quantified by means of two commercial ELISAs. Transactivation of the AR, AR-V7 and Q641X was determined by reporter gene assays. Cell proliferation was measured using a colorimetric MTT-assay.
PFI-1 dose-dependently inhibited transactivation of full-length AR (non- mutated, i.e., wild-type or point-mutated/promiscuous forms) without affecting their cellular protein levels. Moreover, PFI-1 was active against C-terminally truncated constitutively active ARs like AR-V7 and Q641X. Prostate cancer cells exhibiting a transcriptionally active AR-signaling complex (LNCaP, 22Rv1) were more susceptible to the growth-inhibitory effects than the AR-negative PC-3 cells.
The quinazolinone PFI-1 is a highly efficient inhibitor of AR-signaling-competent prostate cancer cells in vitro. PFI-1 could serve as a lead compound for the development of new therapeutics able to block AR/AR-V7 signaling in advanced prostate cancer.
KeywordsBET inhibitor BRD4 Androgen receptor AR-V7
The authors wish to thank Beate Godau and Christine Marschke for expert technical assistance.
MCH: data collection and protocol development; MHR: data collection; FZ: data collection; SP: data analysis; ASM: data analysis and manuscript writing/editing; MVC: project development, data analysis, and manuscript writing.
Compliance with ethical standards
Conflict of interest
The authors declare that they have no conflict of interest.
Research involving human participants and/or animals
This article does not contain any studies with human participants or animals performed by any of the authors.
- 2.Lapouge G, Erdmann E, Marcias G, Jagla M, Monge A, Kessler P, Serra S, Lang H, Jacqmin D, Bergerat JP, Céraline J (2007) Unexpected paracrine action of prostate cancer cells harboring a new class of androgen receptor mutation—a new paradigm for cooperation among prostate tumor cells. Int J Cancer 121:1238–1244CrossRefGoogle Scholar
- 3.Han D, Gao S, Valencia K, Owiredu J, Han W, de Waal E, Macoska JA, Cai C (2017) A novel nonsense mutation in androgen receptor confers resistance to CYP17 inhibitor treatment in prostate cancer. Oncotarget 8:6796–6808Google Scholar
- 4.Asangani IA, Dommeti VL, Wang X, Malik R, Cieslik M, Yang R, Escara-Wilke J, Wilder-Romans K, Dhanireddy S, Engelke C, Iyer MK, Jing X, Wu YM, Cao X, Qin ZS, Wang S, Feng FY, Chinnaiyan AM (2014) Therapeutic targeting of BET bromodomain proteins in castration-resistant prostate cancer. Nature 510:278–282CrossRefGoogle Scholar
- 10.Fish PV, Filippakopoulos P, Bish G, Brennan PE, Bunnage ME, Cook AS, Federov O, Gerstenberger BS, Jones H, Knapp S, Marsden B, Nocka K, Owen DR, Philpott M, Picaud S, Primiano MJ, Ralph MJ, Sciammetta N, Trzupek JD (2012) Identification of a chemical probe for bromo and extra C-terminal bromodomain inhibition through optimization of a fragment-derived hit. J Med Chem 55:9831–9837CrossRefGoogle Scholar
- 11.Picaud S, Da Costa D, Thanasopoulou A, Filippakopoulos P, Fish PV, Philpott M, Fedorov O, Brennan P, Bunnage ME, Owen DR, Bradner JE, Taniere P, O’Sullivan B, Müller S, Schwaller J, Stankovic T, Knapp S (2013) PFI-1, a highly selective protein interaction inhibitor, targeting BET bromodomains. Cancer Res 73:3336–3346CrossRefGoogle Scholar
- 20.Dalal K, Roshan-Moniri M, Sharma A, Li H, Ban F, Hassona MD, Hsing M, Singh K, LeBlanc E, Dehm S, Tomlinson Guns ES, Cherkasov A, Rennie PS (2014) Selectively targeting the DNA-binding domain of the androgen receptor as a prospective therapy for prostate cancer. J Biol Chem 289:26417–26429CrossRefGoogle Scholar
- 25.Fu LL, Tian M, Li X, Li JJ, Huang J, Ouyang L, Zhang Y, Liu B (2015) Inhibition of BET bromodomains as a therapeutic strategy for cancer drug discovery. Oncotarget 6:5501–5516Google Scholar
- 31.Asangani IA, Wilder-Romans K, Dommeti VL, Krishnamurthy PM, Apel IJ, Escara-Wilke J, Plymate SR, Navone NM, Wang S, Feng FY, Chinnaiyan AM (2016) BET bromodomain inhibitors enhance efficacy and disrupt resistance to AR antagonist in the treatment of prostate cancer. Mol Cancer Res 14:324–331CrossRefGoogle Scholar
- 32.Shah N, Wang P, Wongvipat J, Karthaus WR, Abida W, Armenia J, Rockowitz S, Drier Y, Bernstein BE, Long HW, Freedman ML, Arora VK, Zheng D, Sawyers CL (2017) Regulation of the glucocorticoid receptor via a BET-dependent enhancer drives antiandrogen resistance in prostate cancer. Elife 6:e27861. https://doi.org/10.7554/elife.27861 CrossRefGoogle Scholar
- 33.Filippakopoulos P, Qi J, Picaud S, Shen Y, Smith WB, Fedorov O, Morse EM, Keates T, Hickman TT, Felletar I, Philpott M, Munro S, McKeown MR, Wang Y, Christie AL, West N, Cameron MJ, Schwartz B, Heightman TD, La Thangue N, French CA, Wiest O, Kung AL, Knapp S, Bradner JE (2010) Selective inhibition of BET bromodomains. Nature 468:1067–1073CrossRefGoogle Scholar